CN103655909A - Application of compound thrombosis capsule in aspect of kidney protection - Google Patents
Application of compound thrombosis capsule in aspect of kidney protection Download PDFInfo
- Publication number
- CN103655909A CN103655909A CN201310715645.9A CN201310715645A CN103655909A CN 103655909 A CN103655909 A CN 103655909A CN 201310715645 A CN201310715645 A CN 201310715645A CN 103655909 A CN103655909 A CN 103655909A
- Authority
- CN
- China
- Prior art keywords
- kidney
- thrombosis
- fufang xueshuantong
- xueshuantong jiaonang
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003734 kidney Anatomy 0.000 title claims abstract description 29
- 208000007536 Thrombosis Diseases 0.000 title abstract description 11
- 150000001875 compounds Chemical class 0.000 title abstract description 5
- 239000002775 capsule Substances 0.000 title abstract 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229940109239 creatinine Drugs 0.000 claims abstract description 18
- 230000003907 kidney function Effects 0.000 claims abstract description 18
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002158 endotoxin Substances 0.000 claims abstract description 14
- 229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 14
- 230000008021 deposition Effects 0.000 claims abstract description 7
- 239000009277 Panax notoginseng extract Substances 0.000 claims description 45
- 210000004369 blood Anatomy 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 24
- 230000000630 rising effect Effects 0.000 claims description 5
- 108010073385 Fibrin Proteins 0.000 claims description 4
- 102000009123 Fibrin Human genes 0.000 claims description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 229950003499 fibrin Drugs 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 13
- 238000002474 experimental method Methods 0.000 abstract description 9
- 230000015271 coagulation Effects 0.000 abstract description 7
- 238000005345 coagulation Methods 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 201000008383 nephritis Diseases 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 235000013877 carbamide Nutrition 0.000 description 5
- 238000000151 deposition Methods 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 239000000208 fibrin degradation product Substances 0.000 description 4
- 210000005084 renal tissue Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010062237 Renal impairment Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 231100000857 poor renal function Toxicity 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 206010059245 Angiopathy Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000031816 Pathologic Dilatation Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000004220 fundus oculi Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention is applicable to the field of Chinese patent medicines. A lipopolysaccharide-induced rat diffuse intravascular coagulation model is adopted for experimenting, and the experiment result shows that a compound thrombosis capsule can significantly inhibit the rise of kidney-function biochemical indexes including urea nitrogen level and creatinine level, reduces the level of lipopolysaccharide-induced kidney inflammation, and reduces fibrous deposition in a glomeruli. The experiment proves that the compound thrombosis capsule performs the function of protecting a kidney and does not have toxic or side effects. The compound thrombosis capsule can be used for kidney protection in vascular disease treatment in a clinical center.
Description
Technical field
The invention belongs to technical field of Chinese patent medicine, relate in particular to the purposes of FUFANG XUESHUANTONG JIAONANG aspect protection kidney.
Background technology
Studies show that, renal function and cardiovascular disease are closely related.Kidney is the vitals of human body, and its major function is by forming urine, getting rid of unnecessary moisture and refuse in body.In cardiovascular disease after microthrombusis, fibrinolytic secondary strengthens, and causes fibrin degradation product (FDP) etc. to increase.These fiber metabolite overwhelming majority, by the filtration of glomerule blood and the secretion of renal tubules, excrete with urine.So easily forming a large amount of microthrombus depositions, glomerule position finally cause the excretory function of kidney impaired.Meanwhile, after impaired renal function, easily there is retention of sodium and water and uremia, thereby increase the weight of the forward and backward load of heart, affect the systolic and diastolic function of heart and the hemodynamic state of body, further cause or increase the weight of cardiovascular disease.In addition, during nephropathy, because the damage of endotheliocyte discharges thrombosis element, easily form thrombosis, and the Endothelin discharging also can cause hypertension, so the pathological changes of kidney can increase the weight of hypertension and thrombosis.Visible, normally whether being closely related with cardiovascular event of renal function.
Glomerular filtration rate is one of inspection of reaction renal function, and it is in damaged condition that filtration rate reduces expression renal function.Creatinine and blood urea nitrogen are conventional renal function biochemical indicator.Creatinine is a kind of refuse that human muscle produces, and because creatinine is almost all discharged by kidney, and is seldom subject to the impact of food, therefore reflects the function of kidney relatively objectively, if the creatine concentration in blood raises, illustrates that kidney removes the ability of refuse and decline.In addition, blood urea nitrogen is the metabolite that protein produces after Digestion decomposes, converted in liver through ornithine cycle.If impaired renal function, the ability of getting rid of carbamide declines naturally, and the carbamide in blood is piled up, and the level of blood urea nitrogen will raise.
First is used for the treatment of the oral Chinese medicine of optical fundus blood vessel disease and cardiovascular and cerebrovascular disease China of the common development of FUFANG XUESHUANTONG JIAONANG Shi You Zhongshan University Eye Center and Guangdong Zhongsheng Pharmaceutical Co., Ltd, the compound Chinese patent medicine preparation being formed by Radix Notoginseng, Radix Salviae Miltiorrhizae, the Radix Astragali, Radix Scrophulariae four Chinese medicine, there is blood circulation promoting and blood stasis dispelling, the effect of supplementing QI and nourishing YIN, principal indication is the hold concurrently retinal vein occlusion and the stability angina of effort of syndrome of deficiency of both qi and yin of blood stasis, relates to the treatment in the fields such as fundus oculi disease, cardiovascular and cerebrovascular vessel, nephropathy, nervous system disease simultaneously.FUFANG XUESHUANTONG JIAONANG is protected kind as national secondary Chinese medicine, national emphasis new product, and after listing in 1996, clinical application effect is remarkable, in doctor and patient, has formed public's praise, has brought huge society and economic benefit.
Summary of the invention
The object of the invention is to: the purposes of FUFANG XUESHUANTONG JIAONANG aspect protection kidney is provided, is intended to solve the kidney protection problem in treating cardiovascular disease.
The object of the present invention is achieved like this:
The purposes of FUFANG XUESHUANTONG JIAONANG aspect protection kidney,
Outstanding advantages of the present invention is: the present invention is by adopting lipopolysaccharide-induced rat disseminated inravascular coagulation model to test; find that FUFANG XUESHUANTONG JIAONANG can significantly suppress the rising of renal function biochemical indicator blood urea nitrogen and creatinine level; reduce lipopolysaccharide-induced kidney level of inflammation; reduce the fibrin deposition in glomerule; show that FUFANG XUESHUANTONG JIAONANG has protective effect to kidney; and have no toxic and side effects, can be used for the protection to kidney in the treatment of clinical center angiopathy.
Accompanying drawing explanation
Fig. 1 is the experimental result block diagram of the FUFANG XUESHUANTONG JIAONANG that provides of the embodiment of the present invention to renal function index creatinine in serum;
Fig. 2 is the experimental result block diagram of the FUFANG XUESHUANTONG JIAONANG that provides of the embodiment of the present invention to renal function index blood urea nitrogen in serum;
Fig. 3 is the experimental result picture of the FUFANG XUESHUANTONG JIAONANG that provides of the embodiment of the present invention to renal tissues pathology HE staining analysis.
The specific embodiment
In order to make object of the present invention, technical scheme and advantage clearer, below in conjunction with drawings and Examples, the present invention is further elaborated.Should be appreciated that specific embodiment described herein, only in order to explain the present invention, is not intended to limit the present invention.
The present invention is by adopting lipopolysaccharide-induced rat disseminated inravascular coagulation model to test; discovery FUFANG XUESHUANTONG JIAONANG not only tool is significantly improved blood rheological constant; improve the effect of the blood circulation promoting and blood stasis dispelling such as coagulation function, also there is the effect of significant protection renal function.FUFANG XUESHUANTONG JIAONANG can significantly suppress the rising of renal function biochemical indicator blood urea nitrogen and creatinine level, reduces lipopolysaccharide-induced kidney level of inflammation, reduces the fibrin deposition in glomerule.
Below in conjunction with specific experiment, FUFANG XUESHUANTONG JIAONANG is described further in the new purposes aspect protection kidney.
1. laboratory animal:
SD rat, SPF level, male, body weight 150～200 g, are provided by Guangdong Medical Lab Animal Center, the animal quality certification number: SCXK(Guangdong) 2008-0002.
2. medicine grouping and processing:
Normal group: normal saline.
Model control group: adopt tail vein injection lipopolysaccharide to cause rat disseminated inravascular coagulation model, give equal-volume normal saline.
FUFANG XUESHUANTONG JIAONANG low dose group: get FUFANG XUESHUANTONG JIAONANG before experiment, adding normal saline, to be mixed with concentration be 38 mg/ml suspensions.
Dosage group in FUFANG XUESHUANTONG JIAONANG: get FUFANG XUESHUANTONG JIAONANG before experiment and add normal saline to be mixed with concentration be 76 mg/ml suspensions.
FUFANG XUESHUANTONG JIAONANG high dose group: get FUFANG XUESHUANTONG JIAONANG before experiment and add normal saline to be mixed with concentration be 152 mg/ml suspensions.
3. experimental technique:
Get SD rat and be divided at random 5 groups, be i.e. dosage group, FUFANG XUESHUANTONG JIAONANG high dose group in Normal group, model control group, positive drug control group, FUFANG XUESHUANTONG JIAONANG low dose group, FUFANG XUESHUANTONG JIAONANG, every group of 8 rats.Laboratory animal adapted to after one week in feeding environment, and once, administration volume is 10 mL/kg to FUFANG XUESHUANTONG JIAONANG group gastric infusion every day, successive administration 7 days.Normal group, model control group and positive drug control group gavage give same volume normal saline.In the 8th day early morning, after three dosage group gastric infusion 1h of FUFANG XUESHUANTONG JIAONANG, the LPS of tail vein injection 4 mg/kg manufactures rat rat disseminated inravascular coagulation (Disseminated intravascular coagulation, DIC) model.The normal saline of Normal group tail vein injection same volume, the LPS of positive controls tail vein injection 4 mg/kg after the heparin 1h of tail vein injection 500 IU/kg.
Each group is injected 10% chloral hydrate (0.35 mL/100 g) anesthesia at lps injection 4 h pneumoretroperitoneums, postcava blood sampling, after centrifugalize serum, application EOS-880 semi-automatic biochemical analyzer is measured the content of respectively organizing creatinine in serum (Crea) and blood urea nitrogen (Urea).Test kit builds up Bioengineering Research Institute by Nanjing and provides, and the method providing by test kit is measured.
After blood-letting, get immediately rat kidney tissue, with 10% formaldehyde, fix after 24 hours,, paraffin embedding transparent through flowing water washing, gradient concentration 70%, 80%, 90%, 95% and anhydrous alcohol dehydration, dimethylbenzene, with cycle type microtome (LEI is with RMZ135 Germany), be cut into 4um and cut into slices, finally carry out hematoxylin Yihong (Hematoxylin mono-Eosin, HE) dyeing, in the pathologic structure of optical microphotograph Microscopic observation renal tissue.
4. experimental result:
(1) impact of FUFANG XUESHUANTONG JIAONANG on renal function index creatinine, blood urea nitrogen in serum
Creatinine and blood urea nitrogen are conventional renal function biochemical indicator.If impaired renal function, the ability of getting rid of creatinine and carbamide all can decline, and causes the accumulation of creatinine and carbamide in blood, and the level of serum creatinine and blood urea nitrogen will raise.
From table 1, Fig. 1 and Fig. 2, with Normal group comparison, in model group rat blood serum, creatinine and blood urea nitrogen all significantly improve (P<0.01), illustrate that lipopolysaccharide has caused the damage of renal function, and glomerular filtration ability is reduced.In the middle and high dosage group of FUFANG XUESHUANTONG JIAONANG rat blood serum, the level of creatinine and blood urea nitrogen is all than the remarkable reduction of model group, and difference all has statistical significance (P<0.01 or 0.05), and is dose-effect relationship.Illustrate that FUFANG XUESHUANTONG JIAONANG can suppress the reduction of lipopolysaccharide-induced filtration capacity of the kidney.
The impact () of table 1 FUFANG XUESHUANTONG JIAONANG on renal function index creatinine, blood urea nitrogen in serum
In Fig. 1 and 2, experimental group corresponding to each numeral is: 1-Normal group; 2-model control group; 3-positive drug control group (heparin, 500 IU/kg); 4-FUFANG XUESHUANTONG JIAONANG low dose group (380 mg/kg); Dosage group in 5-FUFANG XUESHUANTONG JIAONANG (760 mg/kg); 6-FUFANG XUESHUANTONG JIAONANG high dose group (1520 mg/kg).
(2) impact of FUFANG XUESHUANTONG JIAONANG on renal tissues pathology
Experimental result as shown in Figure 3, a wherein: Normal group; B: model control group; C: positive drug control group (heparin, 500 IU/kg); D: FUFANG XUESHUANTONG JIAONANG low dose group (380 mg/kg); E: dosage group in FUFANG XUESHUANTONG JIAONANG (760 mg/kg); F: FUFANG XUESHUANTONG JIAONANG high dose group (1520 mg/kg).
What this experiment adopted is rat disseminated inravascular coagulation (DIC) model, DIC be take the pathophysiological process that extensively microthrombusis, coagulation disorders, microcirculation exhaustion, Microangiopathic hemolysis are main manifestations in blood vessel, and wherein microthrombusis is the topmost pathophysiological change of DIC.Because kidney has the function of excretion metabolism product, after DIC microthrombusis, fibrinolytic secondary strengthens, cause fibrin degradation product (FDP) etc. to increase, these fiber metabolite overwhelming majority are all to filter by glomerule blood, with urine, excrete, so glomerule position the most easily forms a large amount of microthrombus depositions.
As seen from Figure 3, blank group glomerule clear in structure, renal tubules marshalling, has no expansion and atrophy.Model group rat after tail vein injection LPS 4h, the visible significantly thrombosis (shown in blue arrow) of glomerule, part tubular ectasia, and have obvious bleeding.Though positive drug heparin matched group has part tubular ectasia, has no obvious congestion and bleeding in glomerule.In three dosage groups of FUFANG XUESHUANTONG JIAONANG, low dose group has a small amount of thrombosis to exist, and has significantly hemorrhage; Though it is hemorrhage on a small quantity that middle dosage group has, without obvious thrombosis; High dose group has no obvious congestion and bleeding, and whole structure is suitable with positive drug heparin, is better than in FUFANG XUESHUANTONG JIAONANG, low dose group.
Visible, FUFANG XUESHUANTONG JIAONANG deposits obvious inhibitory action for the fibrinous thrombus of kidney, thereby can improve renal function, and this matches with the rising that FUFANG XUESHUANTONG JIAONANG above can suppress kidney biochemical indicator.
Through experiment; confirm that FUFANG XUESHUANTONG JIAONANG can significantly suppress the rising of renal function biochemical indicator blood urea nitrogen and creatinine level; reduce lipopolysaccharide-induced kidney level of inflammation; reduce the fibrin deposition in glomerule; show that FUFANG XUESHUANTONG JIAONANG has protective effect to kidney; and have no toxic and side effects, can be used for the protection to kidney in the treatment of clinical center angiopathy.
The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, all any modifications of doing within the spirit and principles in the present invention, be equal to and replace and improvement etc., within all should being included in protection scope of the present invention.
Claims (2)
- FUFANG XUESHUANTONG JIAONANG in protection the purposes aspect kidney.
- FUFANG XUESHUANTONG JIAONANG as claimed in claim 1 in protection the purposes aspect kidney; it is characterized in that; be specially FUFANG XUESHUANTONG JIAONANG in the rising that suppresses renal function biochemical indicator blood urea nitrogen and creatinine level; reduce lipopolysaccharide-induced kidney level of inflammation, reduce the purposes of the fibrin deposition in glomerule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310715645.9A CN103655909A (en) | 2013-12-23 | 2013-12-23 | Application of compound thrombosis capsule in aspect of kidney protection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310715645.9A CN103655909A (en) | 2013-12-23 | 2013-12-23 | Application of compound thrombosis capsule in aspect of kidney protection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103655909A true CN103655909A (en) | 2014-03-26 |
Family
ID=50295468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310715645.9A Pending CN103655909A (en) | 2013-12-23 | 2013-12-23 | Application of compound thrombosis capsule in aspect of kidney protection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103655909A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107596009A (en) * | 2017-09-11 | 2018-01-19 | 中山大学 | Purposes of the Compound Xueshuantong preparation in kidney damage medicine caused by treatment hypertension is prepared |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1425412A (en) * | 2002-12-17 | 2003-06-25 | 广东众生药业股份有限公司 | Compound oral thrombolytic preparation and its preparing method |
| JP2011087919A (en) * | 2010-09-06 | 2011-05-06 | Kao Corp | New method for diagnosing constitution and method for counselling using same |
-
2013
- 2013-12-23 CN CN201310715645.9A patent/CN103655909A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1425412A (en) * | 2002-12-17 | 2003-06-25 | 广东众生药业股份有限公司 | Compound oral thrombolytic preparation and its preparing method |
| JP2011087919A (en) * | 2010-09-06 | 2011-05-06 | Kao Corp | New method for diagnosing constitution and method for counselling using same |
Non-Patent Citations (4)
| Title |
|---|
| DONGHONG FANG ET AL: "Fufang Xue Shuan Tong capsules inhibit renal oxidative stress markers and indices of nephropathy in diabetic rats", 《EXPERIMENTAL AND THERAPEUTIC MEDICINE》 * |
| QIAN ZHANG ET AL: "Attenuating effect of Fufang Xueshuantong Capsule on kidney function in diabetic nephropathy model", 《J NAT MED》 * |
| 庞戈红等: "复方血栓通胶囊在儿童肾病综合征高凝状态的临床应用", 《广东医学》 * |
| 张祯: "复方血栓通胶囊对早期糖尿病肾病患者血清炎性指标的影响", 《中国医药指南》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107596009A (en) * | 2017-09-11 | 2018-01-19 | 中山大学 | Purposes of the Compound Xueshuantong preparation in kidney damage medicine caused by treatment hypertension is prepared |
| CN107596009B (en) * | 2017-09-11 | 2021-02-23 | 中山大学 | Application of compound thrombus clearing preparation in preparing medicine for treating renal damage caused by hypertension |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gao et al. | Restricted intravenous fluid regimen reduces the rate of postoperative complications and alters immunological activity of elderly patients operated for abdominal cancer: a randomized prospective clinical trail | |
| CN102908355A (en) | Medicinal composition and application thereof | |
| CN114588169A (en) | Application of fritillaria iso-steroid alkaloid monomer | |
| CN101856418B (en) | Pharmaceutical preparation for preventing nephritis and preparation method thereof | |
| CN104173503B (en) | The Chinese herbal granules of the preparation method of a kind of Chinese herbal granules and preparation thereof and purposes | |
| CN103191204B (en) | Medicine composite for treating chronic kidney diseases and preparation method and application of medicine composite | |
| CN103655910B (en) | Application of compound thrombosis capsule inn aspect of liver protection | |
| EP3403664A1 (en) | Use ofcistanche tubulosa | |
| CN103655909A (en) | Application of compound thrombosis capsule in aspect of kidney protection | |
| CN103893283A (en) | Traditional Chinese medicine composition for treatment of chronic renal diseases and chronic renal failure and its preparation method and use | |
| CN105560265B (en) | Purposes of the Bupleurum chinense polysaccharide in the drug for preparing prevention diabetic nephropathy | |
| CN102846793A (en) | Composition for stagnant blood constitution, and preparation method and application of composition | |
| CN103211833B (en) | Application of icariin in preparation of medicaments for treating gout | |
| CN104161850A (en) | Preparation method of Chinese herbal extract, prepared Chinese herbal extract and application | |
| CN101306091B (en) | Use of prince feather and fleabane combination in preparing medicament for treating kidney disease | |
| CN1951380A (en) | Medical usage of salvianolic acid B salt and total salvianolic acid | |
| CN103006832B (en) | Chinese herbal combination for raising blood platelets and preparation method of combination | |
| CN106963803A (en) | Application of the gynostemma pentaphyllum total flavones in the medicine for preparing preventing and treating myocardial hypertrophy | |
| CN106389764A (en) | Traditional Chinese medicine preparation, and preparation and application thereof | |
| CN102824593B (en) | Chinese patent medicine for treating chronic renal failure | |
| CN103417565B (en) | The application of depolymerization glycosaminoglycan extracted from sea cucumber in preparation control thrombotic diseases medicine | |
| CN1660218A (en) | Chinese materia medica preparation for treating andropathy | |
| CN103893286A (en) | Traditional Chinese medicinal preparation for treating chronic renal disease and preparation method thereof | |
| Nagasaka et al. | Report on four cases of chronic renal failure effectively treated with astragali radix | |
| CN104173506A (en) | Traditional Chinese medicine extract, as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140326 |